Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $96.3B | $1.7B | $2.2B | $3.2B | 1.7% | 2.3% |
| 2025-12-31 | $106.2B | $1.2B | $1.7B | $1.1B | 1.1% | 1.6% |
| 2025-09-30 | $103.2B | $1.1B | $1.5B | $2.2B | 1.1% | 1.4% |
| 2025-06-30 | $97.8B | $0.8B | $1.1B | $-1.1B | 0.8% | 1.1% |
| 2025-03-31 | $90.8B | $1.3B | $1.7B | $7.5B | 1.4% | 1.8% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-05-07 | 11.69 | 11.57 | +1.1% |
| 2026-02-04 | 9.34 | 9.27 | +0.7% |
| 2025-11-05 | 9.86 | 9.05 | +8.9% |
| 2025-08-06 | 8.26 | 8.15 | +1.4% |
| 2025-05-08 | 10.12 | 9.83 | +3.0% |
| 2025-02-05 | 8.03 | 7.99 | +0.5% |
| 2024-11-06 | 7.07 | 6.87 | +2.9% |
| 2024-08-07 | 7.88 | 7.21 | +9.3% |
| 2024-05-07 | 6.18 | 6.36 | -2.8% |
| 2024-02-07 | 7.74 | 7.05 | +9.8% |
| 2023-11-01 | 6.23 | 6.15 | +1.3% |
| 2023-08-02 | 7.27 | 5.87 | +23.9% |
| 2023-05-08 | 7.19 | 7.12 | +0.9% |
| 2023-02-01 | 6.90 | 6.36 | +8.4% |
| 2022-11-01 | 6.06 | 6.10 | -0.7% |
| 2022-08-03 | 5.83 | 5.30 | +10.1% |
| 2022-05-05 | 5.83 | 6.04 | -3.5% |
| 2022-02-02 | 6.15 | 5.42 | +13.6% |
| 2021-11-01 | 6.15 | 4.66 | +32.0% |
| 2021-08-03 | 5.56 | 4.14 | +34.3% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| MCK ★ | $89B | 19.2 | 14.6 | 0.2 | 13.8 | -40.7 | 3.6% | 6.0% | 37.2% | 6.39% |
| LLY | $949B | 37.7 | 23.9 | 13.1 | 27.3 | 30.5 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $343B | 28.5 | 18.1 | 0.8 | 18.5 | 3.5 | 18.8% | 2.0% | 0.7% | 5.15% |
| JNJ | $537B | 25.8 | 17.5 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $286B | 32.6 | 12.1 | 4.3 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.92% |
| ABBV | $381B | 105.1 | 13.3 | 6.1 | 14.8 | -57.2 | 72.0% | 12.4% | -46.2% | 5.47% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $179B | 26.5 | 17.7 | 4.0 | 19.4 | 3.4 | 40.9% | 6.2% | 11.3% | 3.08% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 38.3%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 11,418,384 | 9.50% |
| Vanguard Capital Management LLC | 7,960,724 | 6.62% |
| State Street Corporation | 5,731,756 | 4.77% |
| FMR, LLC | 3,603,423 | 3.00% |
| JPMORGAN CHASE & CO | 3,268,340 | 2.72% |
| Franklin Resources, Inc. | 3,063,145 | 2.55% |
| Geode Capital Management, LLC | 2,903,848 | 2.42% |
| Massachusetts Financial Services Co. | 2,900,233 | 2.41% |
| Vanguard Portfolio Management LLC | 2,883,068 | 2.40% |
| Morgan Stanley | 2,299,625 | 1.91% |
Insider activity · 90d
No insider trades for MCK in last 90d.
Analyst estimates
yfinanceConsensus: none (mean None). Distribution requires FINNHUB_API_KEY.
SEC filings
No CIK found for MCK.
About
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it of…